Fate Therapeutics could secure as much as $69 million from an initial public offering, according to an SEC filing. The San Diego-based firm plans to use the money to further develop ProHema, its umbilical cord blood-based product designed to enhance the success of bone marrow transplants, and other preclinical-stage products, and for other corporate purposes.

Related Summaries